Molecules with specificity for CD45 and CD79

Abstract

The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.

The invention claimed is: 
     
       1. An antibody comprising a binding domain specific to antigen CD45 and a binding domain specific to antigen-CD79b,
 wherein the binding domain specific to the antigen CD45 comprises: 
 3 heavy chain CDRs comprising SEQ ID NO: 128 for CDRH1, SEQ ID NO: 129 for CDRH2 and SEQ ID NO: 130 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 125 for CDRL1, SEQ ID NO: 126 for CDRL2 and SEQ ID NO: 127 for CDRL3; and 
 wherein the binding domain specific to the antigen CD79b comprises: 
 3 heavy chain CDRs comprising SEQ ID NO: 88 for CDRH1, SEQ ID NO: 89 for CDRH2 and SEQ ID NO: 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 85 for CDRL1, SEQ ID NO: 86 for CDRL2 and SEQ ID NO: 87, for CDRL3. 
 
     
     
       2. The antibody according to  claim 1 , wherein the antibody is bispecific or trispecific. 
     
     
       3. The antibody according to  claim 1 , wherein the antibody is a fusion protein. 
     
     
       4. The antibody according to  claim 1 , wherein the antibody format is selected from diabody, scdiabody, triabody, tandem scFv, FabFv, Fab′Fv, FabdsFv, Fab-scFv, Fab-dsscFv, Fab-(dsscFv)2 diFab, diFab′, tribody, tandem scFv-Fc, scFv-Fc-scFv, scdiabody-Fc, scdiabody-CH3, Ig-scFv, scFv-Ig, V-Ig, and Ig-V. 
     
     
       5. The antibody according to  claim 1 , wherein each binding domain is monospecific. 
     
     
       6. The antibody according to  claim 1 , wherein the antibody comprises no more than one binding domain which is specific to CD45 and no more than one binding domain which is specific to CD79b. 
     
     
       7. The antibody according to  claim 1 , wherein the binding domain which is specific to CD45 and the binding domain which is specific to CD79b are independently selected from a Fab, scFv, Fv, dsFv and dsscFv. 
     
     
       8. The antibody according to  claim 1 , wherein the binding domains are humanised. 
     
     
       9. The antibody according to  claim 1 , which further comprises a binding domain specific to serum albumin. 
     
     
       10. A composition comprising one or more multispecific antibodies as defined in  claim 1 . 
     
     
       11. A nucleotide sequence encoding a multispecific molecule an antibody as defined in  claim 1 . 
     
     
       12. A vector comprising a nucleotide sequence defined in  claim 11 .